Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
1. A method for treating anemia, comprising administering a therapeutically effective amount of a crystalline Compound (I):
which has an X-ray powder diffraction pattern comprising peaks at 18.1, 20.3, 22.9, 24.0, and 26.3±0.2 °2θ;
to a patient having anemia.
2. A method for treating anemia, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a crystalline Compound (I):
which has an X-ray powder diffraction pattern comprising peaks at 18.1, 20.3, 22.9, 24.0, and 26.3±0.2 °2θ;
to a patient having anemia.
3. The method of claim 1 , wherein the anemia is anemia secondary to or associated with chronic kidney disease.
4. The method of claim 2 , wherein the anemia is anemia secondary to or associated with chronic kidney disease.
5. The method of claim 1 , wherein the crystalline compound comprises less than 5% by weight of any other crystalline form of Compound (I).
6. The method of claim 2 , wherein the pharmaceutical composition comprises less than 5% by weight of any other crystalline form of Compound (I).
7. The method of claim 5 , wherein the anemia is anemia secondary to or associated with chronic kidney disease.
8. The method of claim 6 , wherein the anemia is anemia secondary to or associated with chronic kidney disease.
9. The method of claim 1 , wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.
10. The method of claim 1 , wherein the therapeutically effective amount of the crystalline Compound (I) comprises less than 100 ppm of a compound of Formula (II):
as determined by GC/MS.
11. The method of claim 1 , wherein the therapeutically effective amount of the crystalline Compound (I) comprises less than 5% by weight of any amorphous form of Compound (I).
12. The method of claim 2 , wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.
13. The method of claim 2 , wherein the pharmaceutical composition comprises less than 100 ppm of a compound of Formula (II):
as determined by GC/MS.
14. The method of claim 2 , wherein the pharmaceutical composition comprises less than 5% by weight of amorphous form of Compound (I).
15. A method for treating anemia, comprising administering a therapeutically effective amount of a crystalline Compound (I):
which has an X-ray powder diffraction pattern as shown in FIG. 1 ,
to a patient having anemia.